You can seek FDA approval to launch a generic drug before the expiration of ABILIFY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY:-

You can seek FDA approval to launch a generic drug before the expiration of ABRAXANE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABRAXANE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABRAXANE:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of ACULAR LS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACULAR LS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACULAR LS:-

You can seek FDA approval to launch a generic drug before the expiration of AMITIZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AMITIZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AMITIZA:-

You can seek FDA approval to launch a generic drug before the expiration of ANTIZOL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ANTIZOL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ANTIZOL:-

You can seek FDA approval to launch a generic drug before the expiration of ARGATROBAN IN SODIUM CHLORIDE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ARGATROBAN IN SODIUM CHLORIDE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ARGATROBAN IN SODIUM CHLORIDE:-

You can seek FDA approval to launch a generic drug before the expiration of AUBAGIO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AUBAGIO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AUBAGIO:-

You can seek FDA approval to launch a generic drug before the expiration of AVEED's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AVEED's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AVEED:-

You can seek FDA approval to launch a generic drug before the expiration of AXIRON's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AXIRON's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AXIRON:-

You can seek FDA approval to launch a generic drug before the expiration of BALCOLTRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BALCOLTRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BALCOLTRA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of BELBUCA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELBUCA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELBUCA:-

You can seek FDA approval to launch a generic drug before the expiration of BELEODAQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELEODAQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELEODAQ:-

You can seek FDA approval to launch a generic drug before the expiration of BUNAVAIL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BUNAVAIL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BUNAVAIL:-

You can seek FDA approval to launch a generic drug before the expiration of BYVALSON's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BYVALSON's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BYVALSON:-

You can seek FDA approval to launch a generic drug before the expiration of CARDENE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CARDENE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CARDENE:-